1000025-07-9

Basic information

• Product Name: Vadadustat
• Synonyms: Vadadustat;Vadadustat(AKB-6548/PG-1016548)
• CAS NO: 1000025-07-9
• Molecular Formula: C₁₄H₁₁ClN₂O₄
• Molecular Weight: 306.70114
• Product Categories: API
• Mol File: 1000025-07-9.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 674.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.461±0.06 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.09±0.40(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: Vadadustat(CAS DataBase Reference)
• NIST Chemistry Reference: Vadadustat(1000025-07-9)
• EPA Substance Registry System: Vadadustat(1000025-07-9)

Safety Data

• Hazardous Substances Data: 1000025-07-9(Hazardous Substances Data)

Usage

Description

Vadadustat is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2) and HIF-PH3 (IC50s = 1.1 and 0.39 micromolar, respectively). It stabilizes HIF-1α in mouse hepatocyte nuclear extracts. Vadadustat (50 and 100 mg/kg) increases erythropoietin levels in mouse serum.

Uses

Vadadustat is a novel HIF (Hypoxia-inducible factor) stabilizer. It provides an effective anemia treatment in nondialysis-dependent chronic kidney disease.

Upstream product

• 16063-70-0 2,3,5-trichloropyridine 
• 1415226-40-2 5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxylic acid 
• 823-56-3 2-Fluoro-3,5-dichloropyridine 
• 1415226-39-9 5-(3-chlorophenyl)-3-methoxy-2-cyanopyridine 
• 1415226-38-8 5-(3-chlorophenyl)-3-chloro-2-cyanopyridine 
• 63503-60-6 3-chlorophenylboronic acid 
• 85331-33-5 2-Cyano-3,5-dichloropyridine 
• 56-40-6 glycine 
• 1000025-95-5 methyl (3,5-dihydroxy-2-pyridineformamido)acetate 
• 1000025-96-6 methyl (3-hydroxy-5-trifluoromethanesulfonyloxy-2-pyridinecarboxamido)acetate 
• 616-34-2 methoxycarbonylmethylamine 
• 81719-53-1 3,5-dichloropyridine-2-carboxylic acid 

Relevant articles and documents

MANUFACTURING PROCESS FOR 3,5-DICHLOROPICOLINONITRILE FOR SYNTHESIS OF VADADUSTAT

Disclosed herein are methods and processes of preparing vadadustat or a pharmaceutically acceptable salts thereof, and intermediates (e.g., a compound of Formula (I), (I-F), (II), or (IV), or a pharmaceutically acceptable salts thereof) useful for the syn

Preparation method of valduxostat and intermediate thereof

The invention relates to a preparation method of valduxostat and an intermediate thereof, and belongs to the field of medicinal chemistry. The preparation method comprises the following steps: taking 3-chloro-5-(3-chlorphenyl)-2-cyanopyridine as a starting material, carrying out hydrolysis reaction, and then carrying out condensation reaction to obtain a compound, namely the intermediate; and further reacting the intermediate compound to obtain vadadustat. The method has the advantages of short route, simple and easily available raw materials, low cost and mild reaction conditions, and is suitable for industrial large-scale production.

Preparation method of pyridine cyclic compound

The invention provides a preparation method of a pyridine cyclic compound, and belongs to the field of pharmaceutical chemicals. The method comprises the steps: mixing 3,5-dihydroxypicolinic acid, concentrated sulfuric acid and an alcohol solvent, and performing esterification reaction to obtain 3,5-dihydroxypicolinic acid methyl ester; then sequentially carrying out protection group feeding and ammoniation to obtain {[5-(3-chlorphenyl)-3-hydroxypyridin-2-yl]amino}acetic acid. The product produced by the method has the characteristics of high purity, high yield, low cost, simple operation andstable process.